Table 3.
Summary of categorical patient characteristics at the time of the first dose for patients in the population pharmacokinetic analysis
| N (%) | N (%) | ||
|---|---|---|---|
| Sex | Concomitant cisplatin | ||
| Female | 200 (25) | Without cisplatin | 90 (11) |
| Male | 607 (75) | With cisplatin | 717 (89) |
| Race | Concomitant gemcitabine | ||
| Other | 43 (5) | With gemcitabine | 337 (42) |
| Caucasian | 688 (85) | Without gemcitabine | 470 (58) |
| Black/African American | 17 (2) | ECOG | |
| Asian | 55 (7) | 0 | 263 (33) |
| American Indian/Alaskan native | 2 (0) | 1 | 484 (60) |
| 2 | 45 (6) | ||
| Multiple | 2 (0) | Missing | 15 (2) |
| Ethnicity | Regimen | ||
| Hispanic or Latino | 86 (11) | Weekly | 40 (5) |
| Not Hispanic or Latino | 720 (89) | Every 2 weeks | 6 (1) |
| Missing | 1 (0) | Days 1 and 8 every 3 weeks | 761 (94) |
ECOG Eastern Cooperative Oncology Group